Phase II study of a high-dose ifosfamide-based chemotherapy regimen with growth factor rescue in recurrent aggressive NHL. High response rates and limited toxicity, but limited impact on long-term survival

Bone Marrow Transplantation

Volumn 27, Issue 4, 2001, Pages 397-404

  Van Besien, K ^a   Rodriguez, A ^a   Tomany, S ^b   Younes, A ^a   Donato, M ^a   Sarris, A ^a   Giralt, S ^a   Mehra, R ^a   Andersson, B ^a   Gajewski, J ^a   Champlin, R ^a   Cabanillas, F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b AMERICAN MEDICAL ASSOCIATION   (United States)

Author keywords

Lymphoma; Prognostic factors; Transplantation

Indexed keywords

ACETYLCYSTEINE; ANTIBIOTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; EPIRUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IDARUBICIN; IFOSFAMIDE; LACTATE DEHYDROGENASE; MELPHALAN; MESNA; METHOTREXATE; METHYLPREDNISOLONE; MITOGUAZONE; MITOXANTRONE; PREDNISOLONE; STEROID;

ADOLESCENT; ADULT; ANTIBIOTIC PROPHYLAXIS; APHERESIS; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER GRADING; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DOSE RESPONSE; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; EVALUATION; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LARGE CELL LYMPHOMA; LUNG TOXICITY; MALE; MALIGNANT TRANSFORMATION; MORTALITY; MULTIVARIATE ANALYSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PHENOTYPE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SALVAGE THERAPY; STEM CELL; STEM CELL TRANSPLANTATION; SURVIVAL; T LYMPHOCYTE; THROMBOCYTE TRANSFUSION; TOXICITY; TREATMENT OUTCOME;

ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS, ALKYLATING; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; IFOSFAMIDE; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 17744383556     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1702793     Document Type: Article

References (44)

1. ESHAP-an effective chemotherapy regimen in refractory and relapsing lymphoma: A 4 year follow-up study
2. Results of a salvage treatment program for relapsing lymphoma: MINE consolidated with ESHAP
3. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma
4. The international prognostic index correlates to survival in patients with aggressive lymphomas in relapse: Analysis of the PARMA trial
5. MINE-ESHAP-BEAC: An induction consolidation program for relapsed intermediate grade lymphoma
6. Intensive chemotherapy with the BEAC regimen and autologous bone marrow transplantation in patients with refractory or recurrent intermediate grade and immunoblastic lymphoma; toxicity, long-term follow-up and prognostic factors
7. Ice pops to prevent melphalan induced stomatitis
8. Regimen-related toxicity in patients undergoing bone marrow transplantation
9. Intensive reinduction with high-dose ifosfamide/VP16 and ifosfamide/novantrone followed by BEAM and stem cell transplant for patients with recurrent lymphoma
10. Enhancement of cell-mediated cytotoxicity by recombinant tumor necrosis factor (TNFα)
11. Analysis of survival times
12. Regression models and life tables
13. A phase I-II study of high-dose thiotepa, busulfan and cyclophosphamide as a preparative regimen for autologous transplantation for malignant lymphoma
14. Sequential intense dose chemotherapy and peripheral stem cell support in refractory lymphoma
15. The role of dose intensity in determining outcome in intermediate-grade non-Hodgkin's lymphoma
16. Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem cell infusion in patients with cancer
17. 5-Year results of dose-intensive sequential adjuvant chemotherapy for women with high-risk node-positive breast cancer: A phase II study
18. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas
19. Ifosfamide, carboplatin, and etoposide: A highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin's lymphoma
20. Quantitative relationships between circulating leukocytes and infections in patients with acute leukemia
21. Intensive dose ifosfamide and etoposide with G-CSF for stem cell mobilization in patients with non-Hodgkin's lymphoma
22. Effect of different chemotherapy regimens on peripheral-blood stem-cell collections in patients with breast cancer receiving granulocyte colony-stimulating factor
23. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma
24. Stem cell mobilization in resistant or relapsed lymphoma: Superior yield of progenitor cells following a salvage regimen comprising ifosphamide, etoposide and epirubicin compared to intermediate-dose cyclophosphamide
25. E-SHAP, inadequate treatment for poor prognosis recurrent lymphoma
26. The international prognostic index predicts for outcome following autologous stem cell transplantation in patients with relapsed and primary refractory intermediate-grade lymphoma
27. Time to relapse has prognostic value in patients with aggressive lymphoma enrolled on to the Parma trial
28. Risk-assessment in diffuse large cell lymphoma at first relapse. A study of the Italian intergroup for lymphomas
29. Evaluation of the Revised European-American Lymphoma classification confirms the clinical relevance of immunophenotype in 560 cases of aggressive non-Hodgkin's lymphoma
30. Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)
31. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma
32. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age
33. Mobilisation of blood progenitor cells with ifosfamide and etoposide (VP-16) in combination with recombinant human G-CSF (Filgrastim) in patients with malignant lymphomas or solid tumours
34. Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma
35. + cell yields and engraftment in patients with non-Hodgkin's lymphomas and Hodgkin's disease
36. VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease
37. Ifosfamide and vinorelbine: An active regimen for patients with relapsed or refractory Hodgkin's disease
38. Dexamethasone, etoposide, ifosfamide, and cisplatin as second-line therapy in patients with aggressive non-Hodgkin's lymphoma
39. Dexamethasone, cytarabine, ifosfamide, and cisplatin as salvage therapy in non-Hodgkin lymphoma
40. Ifosfamide and etoposide-based chemotherapy as salvage and mobilizing regimens for poor prognosis lymphoma
41. Epic as an effective, low toxicity salvage therapy for patients with poor risk lymphoma prior to beam high dose chemotherapy and peripheral blood progenitor cell transplantation
42. Salvage chemotherapy with IAPVP-16 for advanced refractory or relapsed follicular lymphomas
43. Conventional salvage chemotherapy vs high-dose therapy with autografting for recurrent or refractory Hodgkin's disease patients
44. High-dose ifosfamide and etoposide infusion plus methylprednisolone for refractory or relapsed aggressive non-Hodgkin's lymphoma